EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 3.0

Defining Treatment Response in Pediatric Asthma Pharmacogenomics: Comments on "Gene Polymorphisms Associated with Treatment Response of Asthma in Chinese Children” [Letter]

Ercan Yılmaz iD

Journal of Asthma and Allergy · 2026-09 · Volume 19 · 1-2

DOI: 10.2147/jaa.s654536 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Asthma and Allergy, 2026-09. Verfasst von Ercan Yılmaz. Beteiligte Einrichtung: Inonu University, Faculty of Medicine, Pediatric Allergy and Immunology Department, Malatya, Turkey. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

I read with great interest the study by Zhu et al investigating genetic polymorphisms associated with asthma susceptibility and response to budesonide/formoterol in Chinese children. 1 Identifying reproducible pharmacogenomic markers of treatment response is an important step toward precision therapy in pediatric asthma.The reported associations between eight single-nucleotide polymorphisms (SNPs) and outcomes during 12 weeks of budesonide/formoterol treatment are therefore intriguing.Before these variants are interpreted as markers that could guide treatment selection, however, two aspects of the treatment-response phenotype deserve clarification.The first concerns the direction of ΔFEV1%.In the Methods, ΔFEV1% is defined as "FEV1% before inhaler therapy -FEV1% after 12 weeks of inhaler therapy", while a ΔFEV1% ≥10% is simultaneously defined as clinically significant improvement.1 These definitions point in opposite directions.If FEV1% increased from 70% to 85%, for example, the stated formula would yield -15 rather than +15.The Results, however, appear to use the opposite convention: a value of +16.97 in TBXT-rs2305089 C-allele carriers is described as improvement, whereas -9.10 in TT carriers is described as deterioration.A similar direction is used for LTA4H-rs2540487. 1 This may simply reflect a reversed equation in the Methods rather than an error in the underlying analysis.Nevertheless, the distinction is consequential because the reported efficacy rates for LTC4S-rs730012 and CYSLTR1-rs320995 are defined by the ΔFEV1% ≥10% threshold.1 Clarifying whether ΔFEV1% was calculated as post-treatment minus baseline, and confirming that responder/non-responder classification and the efficacy analyses were based on that intended direction, would substantially strengthen confidence in these findings.In pharmacogenomic studies, precise and reproducible phenotype definition is as important as accurate genotyping. 2 A second issue is whether the reported associations identify drug-specific response or broader prognosis during treatment.The eight SNPs were not linked to a single common response phenotype.ADRB2-rs1042713 and STIP1-rs4980524 were associated with rescue medication use; SLCO2B1-rs2712807 and FCER2-rs28364072 with respiratory infections; TBXT-rs2305089 and LTA4H-rs2540487 with change in FEV1%; and LTC4S-rs730012 and CYSLTR1-rs320995 with the dichotomized FEV1-based efficacy rate. 1 These are clinically relevant outcomes, but they are not interchangeable measures of pharmacologic response.This distinction becomes particularly important because all 89 children in the treatment-response analysis received budesonide/formoterol. 1 Without a comparison treatment or a genotype-by-treatment interaction, an association between genotype and outcome among treated children cannot by itself establish that the genotype predicts differential benefit from budesonide/formoterol. 3 A variant associated with respiratory infections, for example, may reflect infection susceptibility rather than reduced drug efficacy.Likewise, rescue medication use may reflect baseline disease liability,

Autor:innen und Institutionen

  • Inonu University, Faculty of Medicine, Pediatric Allergy and Immunology Department, Malatya, Turkey.

ORCID-Profile: Ercan Yılmaz

Zitieren

APA

Yılmaz, E. (2026). Defining Treatment Response in Pediatric Asthma Pharmacogenomics: Comments on "Gene Polymorphisms Associated with Treatment Response of Asthma in Chinese Children” [Letter]. Journal of Asthma and Allergy, Volume 19, 1-2. https://doi.org/10.2147/jaa.s654536

Vancouver

Yılmaz E. Defining Treatment Response in Pediatric Asthma Pharmacogenomics: Comments on "Gene Polymorphisms Associated with Treatment Response of Asthma in Chinese Children” [Letter]. Journal of Asthma and Allergy. 2026;Volume 19:1-2. doi:10.2147/jaa.s654536

BibTeX
@article{Ylmaz2026,
  author = {Yılmaz, Ercan},
  title = {Defining Treatment Response in Pediatric Asthma Pharmacogenomics: Comments on "Gene Polymorphisms Associated with Treatment Response of Asthma in Chinese Children” [Letter]},
  journal = {Journal of Asthma and Allergy},
  year = {2026},
  volume = {Volume 19},
  pages = {1--2},
  doi = {10.2147/jaa.s654536}
}
Kostenlos starten →